Skip to content
  • Newsroom
    • Overview
    • Press releases
    • Media Coverage
    • Events & presentations
    • Publications
  • Join our team
Adamas
  • About us
    • Overview
    • Our leadership
    • Our journey
    • Grants & giving
    • Contact us
    • Join our team
  • Our purpose
  • Our culture
  • Products & pipeline
    • Overview
    • Our products
    • Our pipeline
    • Publications
  • Investors
    • Dashboard
    • Press releases
    • Quarterly results
    • Financials & filings
    • Events & presentations
    • Stock information
    • Analyst coverage
    • Corporate governance
    • Investor FAQs
    • About us
      • Overview
      • Our leadership
      • Our journey
      • Grants & giving
      • Contact us
      • Join our team
    • Our purpose
    • Our culture
    • Products & pipeline
      • Overview
      • Our products
      • Our pipeline
      • Publications
    • Investors
      • Dashboard
      • Press releases
      • Quarterly results
      • Financials & filings
      • Events & presentations
      • Stock information
      • Analyst coverage
      • Corporate governance
      • Investor FAQs
    • Newsroom
      • Overview
      • Press releases
      • Media Coverage
      • Events & presentations
      • Publications
    • Join our team
  • About us
  • Our purpose
  • Our culture
  • Products & pipeline
  • Investors
  • Newsroom
  • Join our team
Newsroom
  • Overview
  • Press releases
  • Media Coverage
  • Events & presentations
  • Publications
archive hero image

Media coverage

Read about Adamas in the news, including insights into the work we do, the things we care about, and the milestones we’re working towards

Jennifer, person with Parkinson’s, power puncher
View All
Change Order

News Feature

Adamas Pharma higher after positive Gocovri trial data

February 11, 2020

Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.

Seeking Alpha

Read more

News Feature

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Adamas, Allena, Antios, Freeline, Lilly, Longeveron, Merck, TLC.

February 12, 2020

Phase III – Adamas Pharmaceuticals Inc., of Emeryville, Calif. Reported in the Journal of Parkinson’s Disease final results from 2-year open-label study that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using Gocovri (amantadine) extended-release capsules; results demonstrated the treatment effect on motor complications was maintained for at least 2 years; median…

Bioworld

Read more

News Feature

Amantadine Successful in Reducing Dyskinesia: Clinical Takeaways

February 17, 2020

The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).

NeurologyLive

Read more

News Feature

Long-term Gocovri Lessens Parkinson’s Motor Symptoms for at Least 2 Years, Final Phase 3 Data Show

February 20, 2020

Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show.

Parkinson’s News Today

Read more

News Feature

Adamas nabs new U.S. patent covering Gocovri in Parkinson’s

May 13, 2020

The USPTO has issued a new patent to Adamas Pharmaceuticals (ADMS +1.4%) covering a method [Gocovri (amantadine)] of reducing “OFF” time and increasing “ON” time in Parkinson’s disease patients, the second patent it has received covering the reduction of “OFF” time.

Seeking Alpha

Read more

News Feature

Largest Biopharma Companies in the Greater Bay Area

May 22, 2020

Ranked by Bay Area employees Locally Researched by: Ahalya Srikant, San Francisco Business Times May 22, 2020, 3:00am PDT This List includes biopharmaceutical companies located in the Greater Bay Area, which is defined as Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano and Sonoma counties.

Bizjournal

Read more

News Feature

Gocovri Before FDA as Possible Bedtime Therapy for ‘Off’ Time in Parkinson’s

June 8, 2020

The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa.

Parkinson’s News Today

Read more

News Feature

BioCom Spotlight: Adamas Pharmaceuticals CEO, Neil McFarlane

July 17, 2020

Adamas Pharmaceuticals continues to develop solutions to neurological diseases with proven leadership and experienced vision.

Biocom

Read More
Connect with us
  • Contact us
  • Privacy policy
  • Online tracking opt-out guide
  • Terms of use
  • Site map

© 2021 Copyright Adamas Pharmaceuticals, Inc. or its related companies. All rights reserved.

© 2021 Copyright Adamas Pharmaceuticals, Inc. or its related companies. All rights reserved.

Please note that our Privacy Policy has recently been updated: Privacy PolicyACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.